MetaCap

AnaptysBio (ANAB) vs UroGen Pharma (URGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AnaptysBio (ANAB) has outperformed UroGen Pharma (URGN) over the past year, gaining 76.6% versus a gain of 6.9%. Over five years, URGN leads with a +127.8% price change compared with +124.8% for ANAB. AnaptysBio is the larger company by market cap ($1.39 billion vs $1.36 billion), about 1.0 times the size.

On valuation, AnaptysBio trades at a lower forward P/E (8.7x vs 11.1x for UroGen Pharma). AnaptysBio converts more of its revenue into profit, with a net margin of -5.6% versus -139.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANAB+76.58%URGN+6.88%
+174%+65%-44%
Nov 21, 20251 yearNov 20, 2026
ANAB+127.09%URGN+129.27%
+318%+117%-84%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANAB versus URGN key metrics
MetricANABURGN
Share price$46.63$27.65
Market cap$1.39B$1.36B
1-day change-1.62%-12.86%
YTD return+44.28%+18.06%
1-year return+76.58%+6.88%
5-year return+124.76%+127.76%
P/E ratio (TTM)7.15—
Forward P/E8.6611.08
EPS (TTM)$6.52$-1.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$234.60M$109.79M
Revenue growth (YoY)+157.01%+21.45%
Net income (latest FY)$-13.23M$-153.49M
Gross margin—88.66%
Operating margin96.72%-113.73%
Net margin-5.64%-139.81%
52-week high$72.36$50.81
52-week low$26.01$16.50
Distance from 52-week high-35.56%-45.58%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+87.11%+119.57%
Average volume496.92K1.11M
Shares outstanding29.73M49.05M
Employees—300
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANAB has outperformed URGN by 69.7 percentage points over the past year.
  • AnaptysBio is more profitable, keeping -5.6 cents of every revenue dollar as net income versus -139.8 cents for UroGen Pharma.
  • AnaptysBio grew revenue faster in its latest fiscal year (+157.01% vs +21.45%).

About AnaptysBio

ANAB stock →

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations

About UroGen Pharma

URGN stock →

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.

Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees

ANAB vs URGN FAQ

Which is bigger, AnaptysBio or UroGen Pharma?

AnaptysBio (ANAB) is larger, with a market capitalization of $1.39B compared with $1.36B for UroGen Pharma (URGN).

Which stock has performed better over the past year, ANAB or URGN?

ANAB returned +76.58% over the past 12 months, compared with +6.88% for URGN (price return, excluding dividends). Past performance does not predict future results.

Are AnaptysBio and UroGen Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons